Sun Pharmaceutical is currently trading at Rs. 602.90, up by 6.00 points or 1.01% from its previous closing of Rs. 596.90 on the BSE.
The scrip opened at Rs. 598.90 and has touched a high and low of Rs. 607.95 and Rs. 597.55 respectively. So far 38,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 650.00 on 09-Oct-2013 and a 52 week low of Rs. 328.00 on 15-Nov-2012.
Last one week high and low of the scrip stood at Rs. 616.00 and Rs. 586.25 respectively. The current market cap of the company is Rs. 1, 24,866 crore.
The promoters holding in the company stood at 63.65% while Institutions and Non-Institutions held 25.95% and 10.40% respectively.
Sun Pharmaceutical Industries, an international specialty pharmaceutical company focused on chronic diseases, and Intrexon Corporation, a leader in synthetic biology, have formed a joint venture (JV) to develop controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide. Initial targets are dry age-related macular degeneration (AMD), glaucoma and retinitis pigmentosa.
The joint venture will leverage Sun Pharma's global capabilities and experience in developing and manufacturing complex dosage forms and specialty pharmaceuticals for niche therapy areas. Intrexon and Sun Pharma will share in both the financing of, and the revenues from, the joint venture.
Through an Exclusive Channel Collaboration (ECC), the joint venture will have access to Intrexon's full suite of proprietary synthetic biology technologies, including the RheoSwitch Therapeutic System (RTS) platform. RTS is a clinically validated method for controlling the location, concentration and timing of protein expression. RTS may address a longstanding limitation of current approaches by enabling patients to receive a targeted biologic therapy without having to endure a lifetime of injections.
The scrip opened at Rs. 598.90 and has touched a high and low of Rs. 607.95 and Rs. 597.55 respectively. So far 38,000 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 650.00 on 09-Oct-2013 and a 52 week low of Rs. 328.00 on 15-Nov-2012.
Last one week high and low of the scrip stood at Rs. 616.00 and Rs. 586.25 respectively. The current market cap of the company is Rs. 1, 24,866 crore.
The promoters holding in the company stood at 63.65% while Institutions and Non-Institutions held 25.95% and 10.40% respectively.
Sun Pharmaceutical Industries, an international specialty pharmaceutical company focused on chronic diseases, and Intrexon Corporation, a leader in synthetic biology, have formed a joint venture (JV) to develop controllable gene-based therapies for the treatment of ocular diseases that cause partial or total blindness in millions of people worldwide. Initial targets are dry age-related macular degeneration (AMD), glaucoma and retinitis pigmentosa.
The joint venture will leverage Sun Pharma's global capabilities and experience in developing and manufacturing complex dosage forms and specialty pharmaceuticals for niche therapy areas. Intrexon and Sun Pharma will share in both the financing of, and the revenues from, the joint venture.
Through an Exclusive Channel Collaboration (ECC), the joint venture will have access to Intrexon's full suite of proprietary synthetic biology technologies, including the RheoSwitch Therapeutic System (RTS) platform. RTS is a clinically validated method for controlling the location, concentration and timing of protein expression. RTS may address a longstanding limitation of current approaches by enabling patients to receive a targeted biologic therapy without having to endure a lifetime of injections.
No comments:
Post a Comment